Background: Compared with other subtypes, triple-negative breast cancer
(TNBC) is more aggressive and has a lower survival rate with chemotherapy being
the only acknowledged systemic treatment option. Recently, PD-1/PD-L1 (programmed
cell death-1 and programmed death-ligand 1) inhibitors have demonstrated survival
benefits in locally advanced or metastatic TNBC patients. However, the effects of
PD-1/PD-L1 inhibitors in neoadjuvant chemotherapy remain controversial.
Methods: Extensive literature searches were conducted in the PubMed,
Embase and Cochrane databases. A pooled odds ratio (OR) with 95% confidence
intervals (CI) was analyzed. Results: Seven randomized controlled trials
(N = 1707) were included. PD-1/PD-L1 inhibitor chemotherapy group showed
pathological complete response (pCR) benefit of 59.0% vs. 40.4% (OR 1.98, 95%
CI 1.38–2.82, p
Announcements
Open Access
Systematic Review
Efficacy and Safety of PD-1/PD-L1 Inhibitors in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
Show Less
1
Department of Breast Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, 471000 Luoyang, Henan, China
*Correspondence: doctorlizhenyu@163.com (Zhen-Yu Li)
Clin. Exp. Obstet. Gynecol. 2023, 50(9), 185;
https://doi.org/10.31083/j.ceog5009185
Submitted: 28 March 2023 | Revised: 2 May 2023 | Accepted: 10 May 2023 | Published: 19 September 2023
(This article belongs to the Special Issue Breast Cancer Research and Treatment)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
Keywords
PD-1/PD-L1 inhibitors
neoadjuvant therapy
pathological complete remission
triple negative breast cancer
Figures
Fig. 1.